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Abstract
The Syrian conflict has caused enormous displacement of a population with a high non-communicable
disease (NCD) burden into surrounding countries, overwhelming health systems’ NCD care capacity.
Médecins sans Frontières (MSF) developed a primary-level NCD programme, serving Syrian refugees
and the host population in Irbid, Jordan, to assist the response. Cost data, which are currently lacking,
may support programme adaptation and system scale up of such NCD services. This descriptive cost-
ing study from the provider perspective explored financial costs of the MSF NCD programme. We esti-
mated annual total, per patient and per consultation costs for 2015–17 using a combined ingredients-
based and step-down allocation approach. Data were collected via programme budgets, facility
records, direct observation and informal interviews. Scenario analyses explored the impact of varying
procurement processes, consultation frequency and task sharing. Total annual programme cost ranged
from 4 to 6 million International Dollars (INT$), increasing annually from INT$4 206 481 (2015) to
INT$6 739 438 (2017), with costs driven mainly by human resources and drugs. Per patient per year
cost increased 23% from INT$1424 (2015) to 1751 (2016), and by 9% to 1904 (2017), while cost per con-
sultation increased from INT$209 to 253 (2015–17). Annual cost increases reflected growing patient
load and increasing service complexity throughout 2015–17. A scenario importing all medications cut
total costs by 31%, while negotiating importation of high-cost items offered 13% savings. Leveraging
pooled procurement for local purchasing could save 20%. Staff costs were more sensitive to reducing
clinical review frequency than to task sharing review to nurses. Over 1000 extra patients could be
enrolled without additional staffing cost if care delivery was restructured. Total costs significantly
exceeded costs reported for NCD care in low-income humanitarian contexts. Efficiencies gained by
revising procurement and/or restructuring consultation models could confer cost savings or facilitate
cohort expansion. Cost effectiveness studies of adapted models are recommended.
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Background
Non-communicable diseases (NCDs) have been responsible for the
majority of deaths worldwide for more than three decades, causing
71% (or 40.5 million) of the 56.9 million global deaths in 2016
(World Health Organization, 2018). NCDs accounted for 77% of
mortality in pre-conflict Syria, led by cardiovascular disease (CVD;
WHO, 2011). Following the prolonged conflict in Syria, now in its
ninth year, almost 6.6 million refugees have fled, mainly into neigh-
bouring countries; 670 000 refugees registered with the United
Nations High Commissioner for Refugees (UNHCR) fled to Jordan.
Irbid, Jordan’s second largest city, hosts over 165 000 refugees, the
largest concentration after Amman (UNHCR, 2018a). Most live in
urban settings, amongst the host community (UNHCR, 2018a).
Previous studies confirmed the high burden of NCDs amongst
Syrian refugees in Jordan (Doocy et al., 2015, 2016) and Jordan’s
public health system has been challenged to respond to this addition-
al burden. Chronic diseases have traditionally been the remit of sec-
ondary and tertiary care in Jordan but national policy has more
recently sought to increase primary care NCD capacity. Meanwhile,
the humanitarian health system has supported the public health sys-
tem response, adapting traditional camp-based care provision to
serve urban-dwelling refugees (UNHCR et al., 2014; UNHCR,
2018b; Akik et al., 2019).
Médecins sans Frontières (MSF), a humanitarian medical organ-
isation, supported the Jordanian health system in providing
primary-level NCD care to Syrian refugees and the vulnerable host
population in Irbid since 2014. Their programme involved a multi-
disciplinary primary care model, which used context-adapted clinic-
al guidelines; medications from the World Health Organization
(WHO) Essential Medicines list; and task sharing, whereby tasks are
redistributed to optimise staff and skill allocation. The service
evolved to include specific mental health and psychosocial support
(MHPSS) and a humanitarian support worker, who linked refugees
to available social and protection services.
While there is a wealth of evidence on cost-effective, primary
care-based clinical management of NCDs in stable high-income
countries, there is limited evidence to guide the delivery of such
interventions in low- and middle-income countries (LMICs), par-
ticularly for conflict-affected and forcibly displaced populations.
The MSF institutional experience regarding NCD programming in
humanitarian settings is equally limited (Miranda et al., 2008;
Ebrahim et al., 2013).
Moreover, there has been limited focus on economic evaluations
of health intervention in humanitarian crises (Makhani et al., 2020).
The sparse evidence on costs of NCD care from a patient perspective
in humanitarian settings has largely been derived from self-reported
household surveys rather than formal costing analyses. In Jordan,
household surveys of urban-based Syrian refugees reported cost as
the main barrier to accessing care for their NCDs (Doocy et al.,
2015; Rehr et al., 2018). MSF provided free NCD consultations,
medications and investigations; but patient accounts recorded as
part of a programme evaluation corroborated the cost barriers faced
when seeking NCD care for NCD conditions not covered by MSF or
for specialist referral. Transport was reported as a barrier to access-
ing NCD care in several surveys, but MSF patients were reportedly
willing to pay transport costs in order to access free care (Doocy
et al., 2015).
In addition, little is known about the costs from the provider per-
spective of delivering NCD care in humanitarian settings. Broad
commentary on the expensive nature of NCD care has highlighted
the perceived high cost of life-long and potentially complex manage-
ment, and the immense strain placed on national healthcare systems
by the influx of refugee populations with a high NCD burden
(Spiegel et al., 2010; UNHCR, 2014, 2015; Slama et al., 2017;
Boulle et al., 2019). UNHCR has sought to address this by support-
ing NCD care at primary level and by exploring health insurance
schemes for refugees (Guterres and Spiegel, 2012; UNHCR, 2014).
To our knowledge, no costing studies describing provider or patient
costs of NCD care in humanitarian settings have been published to
date (Bischoff et al., 2009; Spiegel, 2010; Spiegel et al., 2010, 2014;
Guterres and Spiegel, 2012; Demaio et al., 2013; Jobanputra et al.,
2016; Slama et al., 2017).
Limited available studies have focused on the high cost of statins
to patients in the Eastern Mediterranean and its likely negative im-
pact on adherence (Isma’eel et al., 2012; UNRWA, 2018). Costing
studies of NCD care in both LMICs and high-income countries
point to drugs as high drivers of costs at community level (American
Diabetes Association, 2013; Subramanian et al., 2018), while the
MSF experience across various settings confirms that human resour-
ces (HR) and medications tend to be the most expensive components
of any programme. While there is a growing body of literature on
market shaping strategies to contain rising healthcare costs, such as
regional- or disease-specific pooled procurement mechanisms, there
is little available evidence on the procurement practices of inter-
national non-governmental organisations (NGOs) (Huff-Rousselle
and Burnett, 1996; WHO, 2007; Ewen et al., 2014; USAID, 2014;
Seidman and Atun, 2017; The Global Fund, 2017). This area may
warrant exploration as these organisations engage further in the pro-
vision of chronic NCD care.
To contribute to evidence guiding humanitarian actors in tack-
ling NCDs in complex settings, MSF undertook a mixed methods
Key Messages
• Non-communicable disease (NCD) care is assumed to be expensive but studies of the costs of delivering primary-level
NCD care are lacking in humanitarian settings and in low- and middle-income countries more broadly.
• This descriptive analysis of NCD care delivered in a humanitarian setting found that per patient per year cost ranged
from INT$1424 to 1904, while cost per consultation ranged from INT$209 to 253.
• Costs were primarily driven by recurrent costs, especially drug and human resource costs, which increased in line with
increasing programme complexity.
• Efficiency may be gained through adopting context-adapted drug procurement practices and via human resource redis-
tribution.
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evaluation of the NCD programme in Irbid, north Jordan. Using the
RE-AIM framework, we examined the programme’s Reach,
Effectiveness, Adoption (and acceptance) by patients and staff, and
its Implementation and Maintenance over time, including the costs
and fidelity of implementation. (Glasgow et al., 2019). This article
presents the costing component, describing the annual financial
costs and major drivers of cost from the provider perspective. We
also present sensitivity and scenario analyses performed around the
major cost drivers (drug procurement and staffing) to explore opti-
misation of financial resources. Such data may help humanitarian
organisations and other healthcare providers to design or adapt
cost-effective interventions, and may have implications for the
broader Jordanian health system response and scale up of primary-
level NCD care.
Methods
Study context and intervention
MSF developed an NCD service for Syrian refugees and vulnerable
members of the Jordanian host population at a Ministry of Health
primary care clinic in Irbid in December 2014. Due to space limita-
tions, a second city-centre site was opened within a local NGO clinic
in April 2015. Both sites provided the same vertical services, i.e.
they were not integrated into pre-existing activities at either site.
They had the same staffing makeup, covered the same catchment
area and shared the same management, training and supervision
teams. In fact, both sites were amalgamated in 2019. By the end of
the study period (the end of December 2017), 5045 patients had
been enrolled; 30% were Jordanian, in keeping with government
requirements.
The programme focused on NCDs and NCD risk factors respon-
sible for the greatest mortality in pre-war Syria: hypertension, estab-
lished CVD (angina, myocardial infarction, ischaemic stroke,
transient ischaemic attack, peripheral vascular disease, congestive
heart failure), diabetes types I and II, asthma and chronic obstructive
pulmonary disease (COPD). It targeted those with pre-established
relevant diagnoses or with new diagnoses made by MSF or referring
services. Cancer care was excluded. MSF screened patients for other
target NCDs and engaged in primary/secondary prevention via car-
diovascular risk management, offering healthy living advice and
drug therapy as appropriate. Among patients active by the end of
2017, 67% had hypertension, 60% had diabetes type II, 24% had
CVD, 6% had asthma, 4% had diabetes type I and 2% had COPD,
while over 70% had two or more target NCDs (internal MSF data).
Clinic-based care was initially provided by generalist doctors
with the support of nurses, a health educator, a pharmacist and re-
ception staff. In 2015, the service evolved with the addition of a
family medicine specialist at each site and a home visit service with a
dedicated doctor, nurse and driver. The home visit service was
expanded and MHPSS counsellors and a humanitarian liaison offi-
cer were added in 2016, followed by a physiotherapist in 2017.
Clinical staff were supported by an MSF project team in Irbid and a
coordination team, including an epidemiologist, in Amman. Both
included national and international administrative, logistical, man-
agement and clinical supervisory staff. The programme guidance
stated that patients with uncontrolled disease should attend consul-
tations monthly until stabilised and 3-monthly thereafter. Doctors
performed most consultations. Task sharing to nurses of review
appointments for stable patients was introduced in 2016, but nurses
were performing only 6% of follow-up consultations by the end of
2017. Doctors continued to manage prescribing since nurses were
not permitted to initiate or adjust medications by Jordanian law.
Referrals were not funded by MSF and were excluded from cost cal-
culations. Emergency cases were referred to the Jordanian public
health service. Non-urgent referrals (most frequently ophthalmol-
ogy, cardiology and nephrology) were made to public, private or
other humanitarian providers. Referral patterns varied greatly over
time as the availability of services, e.g. NGO-provided cardiac cath-
eterisation, depended on short donor funding cycles. MSF capped
the total cohort size at 4000 active patients to contain costs.
In many MSF settings, medications and supplies are imported
via European-based procurement units e.g. Amsterdam Procurement
Unit (APU). These command great purchasing power and can obtain
NCD medications at competitive prices. Jordanian regulation, how-
ever, required international NGOs to purchase from the local mar-
ket. MSF approved a number of Jordanian wholesale suppliers,
which met MSF’s strict quality control criteria (MSF, 2016). Three
MSF operational centres (Amsterdam, Paris and Barcelona) active in
Jordan at the time of the study each procured medications separate-
ly, typically in 3–6 monthly order cycles. For drugs unavailable lo-
cally or with an excessive lead time, importation exceptions could
potentially be granted by the Jordan Food and Drug Administration
(Karir et al., 2018).
Cost analysis
This retrospective costing study was undertaken from the provider
perspective, considering MSF as the provider. We used a combin-
ation of standard step-down and ingredients-based costing
approaches, previously used in economic evaluations of health inter-
ventions in LMIC settings (Creese and Parker, 1994; UNAIDS,
2000; Terris-Prestholt et al., 2010; Sweeney et al., 2014). Given the
detailed expenditure data available from MSF, we principally used
step-down costing. This allocates overhead costs or resources in a
step-wise fashion to all overhead departments and then to final cost
centres (a unit that produces output and has a record of resource
consumption, in this case, a clinical consultation) (Pavignani and
Colombo, 2009). Ingredients-based costing requires the identifica-
tion and specification of each resource component or input, used for
delivering an individual service and the unit cost of each in order to
calculate a total endpoint cost. In this case, we estimated how many
minutes staff spent with patients during consultations, the time
taken for supervision and on-job training and we utilised drug con-
sumption data and unit costs.
Annual financial costs, i.e. those costs resulting from actual ex-
penditure on goods and services, were calculated for the study
period 2015–17. Economic costs (costs used by a programme that
could have been productively used elsewhere) were not calculated,
as there was no volunteer time or donated items, and the analysis
took into account all resources used in delivering the programme.
Thus, economic and financial costs would have been very similar.
Data collection and management
A project timeline was developed with input from management staff.
Information relating to the nature, location and mode of delivery of
the NCD services was collected during a field visit in August 2017
by the lead investigator and was supplemented by informal inter-
views with medical supervisory staff. A data analysis tool was
designed to collate and calculate the relevant financial costs by cost
centre. Cost data were collected for the study period from the man-
agement and drug supply chain, including itemised annual expend-
iture data (Supplementary File S1).
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Costs were categorised by service level (coordination, project
and clinic level) and by programme output (Table 1). Overheads
incurred at coordination level were allocated using a factor of 30%,
derived from the mean estimate of the time coordination staff
devoted to the Irbid NCD programme. Overheads from project and
clinic level were allocated at 100%.
Coordination-level costs, involving the management team in
Amman, were categorised into (1) capital, (2) recurrent (other than
HR) and (3) HR costs. Project-level costs, involving the management
team with administration and supervision functions in Irbid, and
clinic-level costs, involving the combined costs of delivering
clinical care at both clinic sites, were also classified into capital and
recurrent costs and coded into specific categories. Specific start-up
costs were not included. We considered that there were no
administrative start-up costs since the pre-existing coordination
team in Amman already had structures and supply chains in place.
At project level, there was a 4-month lead-in period, involving the
international team setting up the service and starting to enroll
patients while gradually recruiting national staff. Costs incurred
during this period were included as capital and recurrent costs, as
appropriate.
Capital costs included building works and purchase of biomed-
ical equipment, office equipment, furnishings and vehicles whose
nominal cost was >100 Euro (Creese and Parker, 1994). Capital
costs were annualised using straight-line depreciation and given a
lifespan of 20 years for building, 5 years for vehicles and 3 years for
equipment (Creese and Parker, 1994).
Recurrent costs included HR (contracted staff salaries and insur-
ance; temporary workers’ fees; experts’ visits); logistics (building
rent, maintenance and operation; office supplies and furnishings);
vehicle maintenance and operation; biomedical equipment and con-
sumables; external laboratory costs; and drugs. Ad hoc training of
clinical and administrative staff was included as a HR cost and was
generally delivered by MSF supervisory staff and/or visiting experts
from headquarters (Supplementary File S1). There was no formal
start-up or refresher training. International staff salary, per diem
and travel costs were attributed to the project personnel budget;
international staff accommodation costs were attributed to project-
level logistics costs. The MSF salary scales, activity data (e.g. oper-
ational reports) and discussion with management and clinical staff
were used to understand costs regarding HR and activities.
Drug costs were analysed as a separate input, as they were antici-
pated to be a major driver of cost and thus a focus of sensitivity and
scenario analyses. We used drug purchase inventories, clinic-level
consumption data, average unit purchase prices provided by the
MSF logistic team (available for 2016 and 2017 only) and the MSF
standard procurement list of drug prices, the ‘Green List’. For 2016
and 2017, missing prices were substituted with the other year’s
price, after appropriate inflation or deflation; deflated 2016 prices
were used to calculate 2015 drug costs. Items categorised as drugs
included medications and drug delivery systems dispensed to
patients (e.g. spacer devices, glucometers, lancets, glucometer strips,
insulin needles).
Descriptive cost analysis
Data were analysed in Microsoft Excel. Costs were incurred in both
Jordanian Dinar (JOD) and Euro (for non-drug items imported via
APU and international staff costs). They were inflated to the base year
2017 and then converted to International Dollars (INT$) by dividing
JOD by the general purchasing power parity (PPP) rate of 0.32 and
Euro by 0.747 (OECD/Eurostat, 2012; OECD, 2017; World Bank
2018). The PPP index is recommended for comparing costs across
countries as it adjusts for differences in relative prices between econo-
mies (Kanavos and Mossialos, 1999). The total annual cost of NCD
clinical care was calculated for each year (2015, 2016 and 2017) by
adding the allocated capital and recurrent costs incurred at clinic, pro-
ject and coordination level. Major cost drivers were identified. Annual
total drug cost and cost per drug were calculated. Endpoint costs were
expressed as cost per patient active at the end of each year, and cost
per consultation per year (using ‘total annual new and follow up med-
ical consultations per year’ as the denominator).
Scenario analyses
Multifactorial scenario analyses were performed around drug and
personnel costs, the key drivers of total cost, to explore areas where
greater cost efficiency might be gained. All were performed around
2017 base case costs.
We explored three hypothetical drug cost scenarios. The first
involved importing all medications and related equipment from
Europe via the APU, since this reflects the practice of MSF programmes
in most other settings. We acknowledge its limited feasibility given
strict regulation and import restrictions in Jordan (Supplementary File
S2). Using the MSF Green list, specific items on the Irbid project medi-
cation list were substituted with clinically equivalent alternatives, and,
in cases where multiple formulations were used in Irbid but only a sin-
gle formulation was available from APU, we proposed purchasing the
equivalent number of milligrams consumed in 2017 from APU
(Supplementary File S3). The second, more feasible scenario, involved
MSF negotiating the right to import a limited number of high-cost
items. Focusing on the programme’s 20 most costly drug items
(Supplementary File S4), we considered importing only items whose
exact formulations were available from APU (n¼10). In both import-
ation scenarios, 16% was added to cover international and national
transport, taxes, import fees and storage costs (including cold chain,
cargo release fees and rent of port storage), based on MSF logistics
data and expert opinion (Karir et al., 2018). A sensitivity analysis was
performed to examine the impact of applying a minimum of 5% and
maximum of 40% to this handling charge, using figures based on MSF
expert opinion. The third, and likely most feasible, scenario involved
leveraging potential purchasing power to negotiate competitive pricing
with local suppliers. We estimated that a 20% price reduction could be
achieved by: (1) joining with other MSF operating sections active in
Jordan; (2) reducing order cycles to 6-monthly; and (3) working with a
reduced number of suppliers.
Additional scenario analyses determined the impact on clinical
staff salary costs of redistributing consultation activity among
Table 1 Overview of clinic outputs (number of active patients and consultations)
Year 2015 2016 2017
Total number of active patients at end of year (% increase from previous year) 2954 3656 (þ24%) 3540 (3%)
Number of consultations per year (% increase from previous year) 20 130 25 912 (þ29%) 26 592 (þ2%)
Note: The number of active patients and consultations increased as the clinic expanded to a second site to increase the service capacity. There was little change
from 2016 to 2017 as the number of active patients was capped for operational reasons.
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medical and nursing staff. These involved varying: (1) the propor-
tion of follow-up consultations for stable patients that were task-
shared to nurses from 6% (the level in December 2017) to 100%;
(2) the proportion of the cohort classified as ’stable’ from 60%
(based on 2017 cohort data analysis) to 70% or 80%; (3) the size of
the active cohort from 3540 (total active patients at the close of
2017) to a maximum of 5000. We did not assess the impact on total
cost of increasing cohort size (i.e. the cost implications of purchasing
and dispensing more medications). Each of the additional scenarios
used the review frequency recommended in MSF guidelines: patients
achieving clinical control were reviewed 3-monthly (4 times per
year); new and uncontrolled patients were reviewed monthly (12
times per year). Based on data from other MSF NCD programmes,
we assumed doctors reviewed all new and uncontrolled patients,
while nurses performed consultations for controlled patients, refer-
ring an estimated 10% back for doctor review (Ansbro, 2018). Since
nurses in Jordan are not permitted to initiate or adjust medications,
we assumed 90% of patients reviewed by nurses remained stable
and continued the same doctor-prescribed medication regime.
The Ethics Review Committee (Reference 12239) and the Ethics
Review Board of the authors’ institutes granted ethical approval for
the conduct of this study.
Results
The total annual financial cost of the MSF Irbid NCD programme
was 4–6 million INT$ with the absolute value increasing annually
by 52% from INT$4 206 481 in 2015 to INT$6 400 611 in 2016
and by a further 5% to INT$6 739 438 in 2017 (Table 2). The large
increase from 2015 to 2016 partly reflects the increasing number of
patients enrolled during that period, facilitated by the addition of a
second clinic site (Table 1).
The main cost drivers each year were drugs (38.4–47.0%) and
HR (35.1–37.9%). Together, these accounted for 73.6–83.4% of
total expenditure (Table 2). Most costs were recurrent (98.4–
98.8%). Most cost categories accounted for a similar proportion of
annual expenditure across years, although drug costs increased by
9% from 2015 to 2016. As expected, the majority of biomedical
equipment expenditure occurred in the first year of operation,
accounting for 6.4% of total costs in 2015 but only 0.1% in 2016
and 2017. The top 20 most costly medication and related equipment
items are presented in Supplementary File S2. The most expensive
item was Mixtard insulin, accounting for 14% of the total
drug budget. Underlying data (Supplementary File S2) show that in-
sulin products and related equipment accounted for 34% of the
total drug budget while statins contributed 15% and inhalers and
spacers 8%.
The per patient per year (PPPY) cost increased by 23% from
2015 to 2016 (INT$1424 to $1751). PPPY increased by a further
9% to INT$1904 in 2017 (Table 2). Similarly, the cost per consult-
ation increased by 18% from 2015 to 2016 (INT$209 to INT$247)
and by a further 3% to INT$253 in 2017.
The majority of costs were incurred at clinic level (75.2–77.2%
of total costs each year), while field and coordination level costs
accounted for a much lower proportion (14.8–17.4% and 5.6–
8.1%, respectively) (Figure 1 and Supplementary File S5). Salaries,
Table 2 Annual cost per cost category and endpoint costs for Irbid NCD Programme for 2015, 2016 and 2017
Year of programme 2015 2016 2017
Type of cost INT$a Annual total (%) INT$ Annual total (%) INT$ Annual total (%)
Capital costs Coordination-level capital investmentb 2872 0.1 8029 0.1 10 160 0.2
Clinical equipment and drug storage 22 883 0.5 29 105 0.5 33 447 0.5
Building work and furnishingsc 22 852 0.5 31 069 0.5 30 961 0.5
Vehicle purchased 0 0.0 32 166 0.5 32 166 0.5
Total capital 48 606 1.2 100 369 1.6 106 733 1.6
Recurrent costs Coordination costs (excl. HRe) 102 815 2.4 85 514 1.3 150 485 2.2
Drugs 1 615 967 38.4 3 008 539 47.0 3 049 381 45.3
Laboratory 360 054 8.6 478 186 7.5 445 169 6.6
Biomedical equipmentf 270 516 6.4 7272 0.1 6177 0.1
Building rent, maintenance, utilities 260 254 6.2 313 152 4.9 370 681 5.5
Recurrent transport costsg 65 379 1.6 129 515 2.0 40 076 0.6
Staff costs including expert visit 1 477 885 35.1 2 269 379 35.5 2 553 894 37.9
Human resources training 5006 0.1 8684 0.1 16 841 0.2
Total recurrent 4 157 874 98.8 6 300 242 98.4 6 632 704 98.4
Total annual costs 4 206 481 6 400 611 6 739 438
Endpoint costs
Cost per patient per yearh 1424 1751 1904
Cost per consultationi 209 247 253
aCosts are presented in 2017 International Dollars (using PPP to convert JOD and Euro nominal costs into INT$).
bCoordination capital investment includes purchase of office furnishings, IT equipment and vehicles; some remodelling work on the rented office in Amman.
cBuilding work and furnishings includes office furnishings, IT equipment and other large items, furniture, large building work costs for the project office and
both clinic sites in Irbid.
dVehicle purchase at project level.
e Includes all recurrent costs at coordination level (building rent, maintenance, transport, etc.) except for human resources (included in the human resources
category).
fRecurrent biomedical equipment used in clinic, e.g. swabs, gloves, glucometer strips.
gRecurrent transport costs: vehicle operation and maintenance, fuel, taxi hire (other than to the international airport, which is included as an international staff
cost).
hCost per patient per year: based on total annual cost divided by total active number of patients at end of relevant year (see Table 1).
iCost per consultation: based on total annual cost divided by total new plus follow-up medical consultations per year. It excludes individual health education or
mental health sessions and group sessions.
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insurance and other costs required when employing Jordanian staff
accounted for a fifth of the total budget.
Table 3 presents several scenarios exploring alternative drug pro-
curement arrangements. Scenario 1 outlines a hypothetical situation
importing all medications and relevant equipment from the APU,
which reflects the procurement model of many MSF programmes in
other contexts. The total drug cost using this scenario was
INT$962 076 (range: 870 845–1 161 127), representing a 68% sav-
ing on the base-case drug cost (62% at maximum import costs) or
31% of total costs.
Scenario 2 reflects a more realistic possibility for this specific
context, whereby MSF would negotiate permission to import 10 of
the top 20 most costly drug items. Significant savings of 29% of
drug costs vs the base case (INT$894 065 or 13% of total costs)
were still possible with this scenario, and were largely retained
(27%; INT$809 937) at our estimated maximum import cost. For
Scenario 3 we estimated, based on local expert opinion, that savings
of 20% could be made compared with the local purchase prices
obtained in 2017. This would result in potential savings of 9% of
total programme costs.
Figure 1 Annual cost per cost level for Irbid NCD Programme for 2015, 2016 and 2017, in International dollars.
Table 3 Scenario analyses exploring options to reduce drug costs (INT$2017)a
Base case (2017) (Table 2) Scenario 1 Scenario 2 Scenario 3
Import all drugs from Amsterdam
Procurement Unit with various
associated import costs (%)
Import 10 of most costly drugs items,
available from MSF Essential Drugs List,




Min. (5%) Expected (16%) Max. (40%) Min. (5%) Expected (16%) Max. (40%)
Drug costs 3 049 381 870 845 962 076 1 161 127 2 116 757 2 155 316 2 239 444 2 439 505
Non-drug costs 3 688 844 3 688 844 3 688 844 3 688 844 3 688 844 3 688 844 3 688 844 3 688 844
Total annual cost 6 739 438 4 559 689 4 650 920 4 849 971 5 805 601 5 844 160 5 928 288 6 128 349
% Change vs base 0 32% 31% 28% 14% 13% 12% 9%
aCosts are presented in 2017 International Dollars (using PPP to convert JOD and Euro nominal costs into INT$).
bThe pooled procurement scenario involved pooling with other MSF sections active in Jordan, reducing the number of suppliers and reducing frequency of
order cycles to 6-monthly.
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Scenario analyses varying factors affecting work pattern are dis-
played in Table 4 (see also Supplementary File S6). The base case
described patient load (3540 active patients) and staffing patterns as
of the end of 2017, using salaries of currently employed doctors
(two specialists and two non-specialists) and nursing time required
for follow-up consultations of stable patients at 2017 rates (6%).
Scenario 1 described the implications of adhering to guideline re-
view intervals for the current cohort, categorising 60% as con-
trolled. In this case, assuming only one specialist doctor was
employed to manage the especially complex patients, 3.5 FTE (full-
time equivalent) doctors and 1.5 FTE nurses were required, resulting
in savings of 6.3% of clinical staff costs. Scenario 2 assumed all
Scenario 1 parameters remained, but the proportion of controlled
patients was increased to 70%, shifting more patients to 3-monthly
nurse-led appointments. Thus, one FTE non-specialist doctor could
be removed, while 0.5 FTE nursing time was added, resulting in clin-
ical staff cost savings of 19.9% (INT$41 822). Scenario 3 proposed
that the cohort could be increased by 1000 for almost the same cost
as the base case (INT$311 387 vs 307 528) using the conditions of
Scenario 2. Scenario 4 suggested that if the control rate could be
increased to 80%, thereby shifting even more patients to 3-monthly
nurse-led reviews, an almost 1500 extra patients could be added to
the cohort for a slightly lower clinical salary cost than current base-
case cost (1.6%; INT$302 457 vs 307 528). Thus, clinical salary
costs were most sensitive to the assumption that 70% of patients
were achieving clinical control and were reviewed by a nurse on a 3-
monthly basis. Clinical salary cost savings could be made with a
similar sized cohort or, as in Scenarios 3 and 4, the cohort could be
increased at a salary cost similar to the current 2017 base-case cost.
Note, in these scenarios, we did not include the increased cost of
drugs that would be incurred if the cohort size was increased.
Discussion
To our knowledge, this is the first study to provide a detailed de-
scription of the costs of providing primary-level NCD care to Syrian
refugees and the local population in the Middle East region, and one
of the few to describe the costs of delivering NCD care in humani-
tarian settings globally. Our findings showed that total costs were
primarily driven by drug and human resource costs and that most
costs were incurred at the clinic level. Our scenario analyses indi-
cated that the greatest cost efficiency could be gained by importing
all medications from Europe, then by importing the top 10 most ex-
pensive items and, finally, by pooling procurement (in this case, be-
tween the various MSF operational centres). Less significant cost
savings could be made through greater use of task shifting.
The total annual financial cost of delivering the MSF NCD pro-
gramme in Irbid increased yearly from 2015 to 2017. This was due
to increasing numbers of active patients over time but also to the de-
livery of a more complex programme requiring greater HR inputs.
The year 2015 saw a gradual addition of staff and services, including
the home visit service, the mental health service and additional
counselling, pharmacy, medical and nursing staff (Ansbro, 2018).
While a greater number of consultations was performed in 2017,
they involved a smaller number of active patients, so fewer patients
were seen more often, thereby reducing efficiency (Table 1).
From a cost structure perspective, costs other than drugs and HR
contributed only one-fifth of the total. Of these, most were recurrent
costs. Capital costs were minimal since MSF rented office and ware-
house premises and space within pre-existing clinics.
Drugs were the major cost driver each year. As discussed, Jordan
legislation requires NGOs to purchase drugs locally, unlike in many
humanitarian contexts where NGOs can import drugs. The costs
involved in insulin therapy (insulin, glucose reagent strips and lan-
cets) featured prominently, despite insulin being prescribed at only
23% of visits in 2017. Atorvastatin accounted for 15% of the total
drug budget in 2017, despite potential under-prescribing (only 25%
of eligible patients were actually prescribed it) (Ansbro, 2018).
The majority of costs were incurred at clinic level, since the drug
budget and clinical staff costs were allocated to this level. The costs
associated with the highly qualified Jordanian medical, paramedical
and support staff (salaries, insurance, medical costs) contributed ap-
proximately two-thirds of the HR budget. The total annual cost
could be reduced by almost 25% (INT$1 657 960 in 2017) if the
costs of MSF’s operational, logistical and medical supervisory sup-
port at central and local level were removed, reflecting potential sav-
ings if such a service were scaled up within a public healthcare
system.
According to our scenario analyses, the total annual drug cost
would be reduced by over two-thirds if MSF were to import all
drugs from Europe at MSF warehouse prices (including import
Table 4 Scenario analysis varying work pattern and patient load





Scenario 2 Task sharing
with 70% controlled
Scenario 3 Task sharing
with 70% controlled
& cohort of 4500
Scenario 4 Task
sharing 80% controlled
and cohort of 5000
Cohort size 3540a 3540 3540 4500 5000
Proportion at clinical control 60%b 60% 70% 70% 80%
Specialist doctorsc 2 1 1 1 1
Non-specialist doctorsc,d 2 2.5 1.5 2 2.5
Nursesc 0.2 1.5 2 2.2e 2.8
Total annual salary costf (INT$ 2017) 307 528 288 208 246 376 311 387 302 457
% Change in cost vs base case n/a 6.3 19.9 þ1.3 1.6
aTotal number of active patients at end of 2017.
bProportion of active cohort that is stable based on cohort analysis.
cFull-time equivalent.
dFigures rounded up to the nearest 0.5 of FTE.
eThis scenario allowed for the dedication of an additional 0.2 FTE nurses to consultations vs Scenario B, who could be redeployed from other activities, such as
triage and patient education.
fAnnual total salary costs of doctors and nurses required to perform new and follow-up medical consultations.
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costs), potentially saving 31% (INT$2 087 305) of total programme
costs. A more realistic scenario importing a limited number of costly
items still resulted in drug cost savings of 12% of total costs. A 9%
reduction in total costs (INT$609 876), obtained via the pooled pro-
curement scenario, offered the least cost savings but may represent
the most feasible option in the current regulatory environment.
Three pharmaceutical originator companies control 96% of the
global insulin market. Significant work has been done to illuminate
the global barriers and challenges in accessing affordable insulin
(Beran et al., 2016; Gotham et al., 2018). Some humanitarian organ-
isations have recently negotiated a reduced price per vial of human
insulin from one originator company, which has introduced differ-
ential pricing for least developed countries, averaging 2.9 USD per
vial in 2019 (Novo Nordisk, 2019). However, there is still signifi-
cant advocacy and policy work to be done by WHO, humanitarian
actors, governments, the research community and advocacy groups
to address global disparities in insulin pricing and availability. In
our analysis, underlying data show that MSF paid 9.81 JOD per vial
in 2017 to local suppliers (30 INT$ using PPP or 13.83 USD using a
direct currency conversion). Clearly, significant savings may be pos-
sible, either through negotiation with local insulin suppliers in
Jordan or via importation. Echoing findings from other contexts, we
also underline the significant additional costs associated with insulin
therapy (glucometers, strips and lancets), which may also be amen-
able to negotiation with manufacturers or suppliers (Beran and
Yudkin, 2010).
Our consultation delivery model scenario analyses demonstrated
that these costs were more sensitive to frequency of patient review
rather than to a change from doctor- to nurse-delivered consulta-
tions. As a greater proportion of patients were categorised as stable,
incrementally greater cost efficiencies resulted, which could be trans-
lated into cost savings or to an expansion of the cohort within the
same budget. Reducing review frequency of stable patients further
still to 6-monthly would clearly result in further cost savings. These
scenarios did not account for the time of other personnel directly
involved in care delivery, such as pharmacists, health educators, tri-
age nurses and reception staff, nor the increase in drug costs that
would be incurred if the cohort size was increased (amounting to
861.41 INT$ annual per patient drug cost at 2017 base-case prices).
Any reduction in HR costs, as demonstrated, would require signifi-
cant restructuring of the programme, staff training and acceptance
by patients, staff, within the local health system, legal and policy
environment.
To our knowledge, there are no available published data to com-
pare endpoint costs of primary-level NCD care delivery either in the
Middle East region or in other humanitarian settings. Unpublished
MSF data report incremental PPPY costs of INT$222 (2015) and
INT$441 (2016), respectively, associated with adding diabetes care
to pre-existing services in a chronic conflict setting in Mweso,
Democratic Republic of Congo and with integrating NCD care with
HIV and general outpatient services in Swaziland. However, com-
parisons must be made cautiously given different programme and
procurement structures and local HR costs. A recent Kenyan study
described patient-level direct annual costs of treatment for NCDs
(hypertension, diabetes, asthma, COPD) at a quasi-public health fa-
cility (including data from MSF-Operational Centre Belgium Kibera
Health Facility). Consultation fees, costs of medications and of
admissions for acute exacerbations were included with total annual
per patient costs ranging from $25.64 to $372.45 (USD 2015)
(Subramanian et al., 2018). The limited data on NCD care available
from countries affected by the Syrian crisis focus on secondary- or
tertiary-level care. A Turkish study showed that annual per patient
cost for outpatient drugs and follow-up was 553.48 Lira (USD
121.38, 2015) for heart failure patients but the cost ingredients used
were not reported (Aras et al., 2016).
There are very limited available data to allow comparison of
costs structures in the delivery of NCD care in LMIC or humanitar-
ian settings. However, the unpublished MSF studies referred to
above are consistent with this study in that HR and drugs accounted
for the bulk of costs. The relatively high cost of insulin and related
equipment has been found in previous studies. A review of medicine
procurement processes and prices for drugs provided in UNRWA
(United Nations Relief and Works Agency for Palestinian Refugees
in the Near East) primary care clinics in 2010, prompted by budget
constraints and the increasing demand for NCD drugs, underscored
the high cost of anti-hypertensive and anti-diabetic medications,
including insulin.
In the past, MSF and other humanitarian actors have tended to
match their Essential Drug Lists to the WHO Essential Medications
List and to set up parallel procurement systems, principally by im-
portation from Europe and elsewhere. In addition, MSF has historic-
ally been less health system focused, and its exacting drug quality
assurance (QA) standards can put it out of step with host country
health systems. However, humanitarian NGOs, including MSF, in-
creasingly provide services that are integrated within national health
systems, especially in protracted crises. Thus, it may be more effect-
ive and ease procurement to match what is available in the local set-
ting and to align with national health system procurement processes,
especially when working in contexts with well-functioning health
systems, such as the Middle East. Humanitarian NGOs may, there-
fore, need to modify their QA standards or to agree on a mutually
acceptable QA approach with Ministries of Health. Furthermore,
aligning with local prescribing practices, formulations and presenta-
tions (e.g. using individually boxed and branded medicines) may
confer an added advantage in terms of acceptability to patients and
local providers, as experience has shown that Syrian patients prefer
to use drugs that are familiar to them (Ansbro, 2018; Garry et al.,
2018).
UNRWA procures most medications via central tender from pre-
qualified suppliers (mostly located in Europe or the Middle East),
while a minority of drugs are procured locally. In the review
described earlier, UNRWA concluded that cost savings could be
made through regular review of medication prices, competitive ne-
gotiation with a larger list of pre-qualified suppliers from a greater
number of regions and via selective participation in Jordan’s Joint
Procurement Department or the Gulf Cooperation Council effective
pooled procurement tender processes (Ewen et al., 2014; Seidman
and Atun, 2017). MSF has also recently undertaken an in-depth as-
sessment of access and affordability of NCD medications in Jordan
and the region, which this article drew on, and concluded that sav-
ings could be made through pooled procurement by all MSF oper-
ational centres present in Jordan, by negotiation with local suppliers
and by selective importation of expensive items . Perhaps the key les-
son is that, given the high costs of providing chronic NCD drugs, hu-
manitarian actors should undertake analyses of the pharmaceutical
supply sector and should incorporate context-specific approaches to
cost-effective procurement when designing or adapting NCD
services.
Limitations
This analysis did not examine direct costs from a patient perspective
or indirect costs of NCDs in this population. Patient-level data were
not examined in terms of service use. Each patient was treated the
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same regardless of diagnosis, date of entry to the cohort, duration of
follow-up or whether an active or defaulting patient. Thus, costs
could not be disaggregated by type of NCD or number/type of
comorbidities, which may be an area for future research. Human re-
source costs for cadres other than doctors were based on staff esti-
mates, rather than on formal staff time observation, which may
have reduced the accuracy of these estimates. We did not include
costs of external referral, which are not paid by MSF. In addition,
given the specific Irbid programme model, separate start-up costs
were not included but internal MSF training and epidemiologist sup-
port were. Wastage was not factored into drug costs. Other actors
would need to take these elements into account if planning a similar
programme.
Our scenario analyses around drugs are specific to the Jordan
drug market and regulatory environment and may not be generalis-
able. However, we have illustrated that cost savings may be made
by adapting procurement strategies to the local market. The HR-
related scenario analyses include assumptions based on the local
context or on other humanitarian contexts and may need to be
adapted as appropriate. Finally, choosing to present costs in INT$
using PPP inflates the nominal JOD cost by a factor of three. Thus,
costs may appear greater than if presented using the direct currency
conversion of 1.41.
We suggest that future research should focus on (i) cost analyses
from the patient perspective; (ii) prospective studies exploring pro-
vider costs on a per patient rather than aggregate basis, and (iii) on
patient adherence and beliefs about medicines. We echo other
authors’ suggestion that the WHO Regional Office for the Eastern
Mediterranean would establish a regional procurement price data-
base similar to that developed elsewhere (Ewen et al., 2014).
Conclusion
Cost estimates regarding the delivery of primary-level NCD care in
humanitarian settings, and in LMICs more broadly, are lacking.
Our study indicates that efficiency may be gained through adopting
context-adapted procurement practices and via human resource re-
distribution. Our costing estimates will inform humanitarian actors
in adapting this programme and in planning future NCD pro-
grammes in similar contexts. They may also have broader implica-
tions for the Jordanian health system response to the Syrian crisis
and may inform policy makers scaling up primary-level NCD care in
resource-constrained or crisis settings elsewhere.
Supplementary data
Supplementary data are available at Health Policy and Planning online.
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